U.S. Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems Market

Benign prostatic hyperplasia (BPH), or the noncancerous enlargement of the prostate gland, is a common condition associated with aging. While the prostate grows throughout a man’s lifetime, bothersome growth typically begins at age 40, and by approximately age 60 more than half of men will have experienced at least some symptoms of BPH; by age 80, an estimated 80% to 90% of men are symptomatic. It is estimated that nearly 15 million men in the United States (U.S.) and 30 million men worldwide experience symptoms of BPH; of this number, an estimated 25% require pharmaceutical or surgical treatment. Due to the aging of the population, the number of men with the condition is expected to follow an upward trend.